{"disease":{"id":"car-t-cell-immunotherapy","name":"car t cell immunotherapy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06571396","title":"Perioperative Risk of Immunotherapy Based Neoadjuvant and Conversion Therapy for Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Qilu Hospital of Shandong University","has_results":false},{"nct_id":"NCT05311566","title":"PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":92,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT03252171","title":"CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Fuda Cancer Hospital, Guangzhou","has_results":false},{"nct_id":"NCT04406610","title":"CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Fuda Cancer Hospital, Guangzhou","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}